Document is current
Any future updates will be listed below
-
Authors
Birtel, Johannes https://orcid.org/0000-0001-7699-2112
Diederen, Roselie M.
Herrmann, Philipp
Kaspar, Sophie
Beck, Bodo B.
Garrelfs, Sander F.
Hoppe, Bernd
Charbel Issa, Peter
-
Funding
Funding for this research was provided by:
Dr. Werner Jackstädt-Stiftung (S0134-10.22)
Bayer Global Ophthalmology Awards Program
NIHR Oxford Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 18 May 2022
Revised: 5 September 2022
Accepted: 22 September 2022
First Online: 19 October 2022
Declarations
:
: JB has been a consultant of Alnylam Pharmaceuticals, Cambridge, MA, USA, and has received a grant from Dicerna Pharmaceuticals, a Novo Nordisk subsidiary, Lexington, MA, USA. PH has received honoraria for lectures from Novartis und Bayer and has received a grant from Novartis. BH has been an employee of Dicerna Pharmaceuticals, a Novo Nordisk subsidiary, Lexington, MA, USA. BBB has received consultation fees from Alnylam Pharmaceuticals, Cambridge, MA, USA. SFG has received grants from Alnylam Pharmaceuticals, Cambridge, MA, USA, and Dicerna Pharmaceuticals, a Novo Nordisk subsidiary, Lexington, MA, USA. The other authors declare no conflicts of interest.
